Comparison
Bremelanotide vs. Triptorelin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
189691-06-3
57773-63-4
Molecular weight
1025.18 g/mol
1311.45 g/mol
Half-life
2.7 h
3 h
Sequence
Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OHpGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2Mechanism of action
Bremelanotide
Bremelanotide is a cyclic peptide that binds non-selectively to melanocortin receptors (MC1R through MC5R) — with highest affinity at MC4R in the central nervous system. The precise role of MC4R activation in sexual behaviour is not fully understood; animal data show effects on hypothalamic circuits. Peripheral effects (blood pressure, hyperpigmentation) are attributed to MC1R/MC2R.
Triptorelin
Triptorelin binds with high affinity to the GnRH receptor in the pituitary. After initial stimulation of LH and FSH secretion (flare phase, about 1-2 weeks), receptor desensitisation follows with consecutive gonadotropin suppression. This results in a reversible chemical castration: in men testosterone, in women oestrogen suppression to the postmenopausal range.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
5
4
of which in humans
5
4
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
2
3